BRAF and melanoma: We observed that CD8+ T cells were relatively scarce in BRAF/MEKi‐insensitive, on‐therapy regrowing melanoma tumors, but abundant in BRAF/MEKi‐sensitive, on‐therapy regressing tumors, as quantified in vehicle‐treated, regressing, and regrowing tumors (Figure5A,B).